Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Operating Leases for 4 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 37.31% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 37.31% year-over-year, with the annual reading at $4.0 million for FY2025, 37.31% down from the prior year.
  • Operating Leases for Q4 2025 was $4.0 million at Fulcrum Therapeutics, down from $4.7 million in the prior quarter.
  • The five-year high for Operating Leases was $12.8 million in Q1 2022, with the low at $4.0 million in Q4 2025.
  • Average Operating Leases over 4 years is $8.4 million, with a median of $8.4 million recorded in 2023.
  • The sharpest move saw Operating Leases dropped 20.05% in 2024, then tumbled 37.31% in 2025.
  • Over 4 years, Operating Leases stood at $10.8 million in 2022, then fell by 20.26% to $8.6 million in 2023, then fell by 25.33% to $6.4 million in 2024, then crashed by 37.31% to $4.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $4.0 million, $4.7 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.